{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:16:45Z","timestamp":1784215005945,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Plasmodium falciparum<\/jats:italic> cysteine-rich protective antigen (<jats:italic>Pf<\/jats:italic>CyRPA) is an invasion complex protein essential for erythrocyte invasion. In contrast to several previously clinically tested merozoite vaccine candidate antigens, <jats:italic>Pf<\/jats:italic>CyRPA is not polymorphic, making it a promising candidate antigen for blood stage vaccine development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Mice and rabbits were immunized with vaccine formulations of recombinantly expressed <jats:italic>Pf<\/jats:italic>CyRPA adjuvanted either with the glucopyranosyl lipid A (GLA) containing adjuvants GLA-LSQ, GLA-SE, GLA-Alum or with Nanoalum. ELISA and indirect immunofluorescence assays (IFA) were used to analyse elicited IgG titers and the <jats:italic>P. falciparum<\/jats:italic> growth inhibitory activity was determined with a standardized in vitro [<jats:sup>3<\/jats:sup>H]-hypoxanthine incorporation assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the mouse experiments, the GLA adjuvanted formulations were superior to the Nanoalum formulation with respect to antibody titer development, IFA sero-conversion rates and in vitro parasite growth-inhibitory activity. In rabbits, the highest titers of parasite growth inhibitory antibodies were obtained with the GLA-SE formulation. Comparable mean ELISA IgG endpoint titers were reached in rabbits after three immunizations with GLA-SE adjuvanted <jats:italic>Pf<\/jats:italic>CyRPA doses of 5, 25 and 100\u00a0\u00b5g, but with 100\u00a0\u00b5g of antigen, only two immunizations were required to reach this titer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>Pf<\/jats:italic>CyRPA formulated with the human-compatible adjuvant GLA-SE represents an attractive vaccine candidate for early clinical testing in a controlled <jats:italic>P. falciparum<\/jats:italic> blood stage challenge trial.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-023-04638-8","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T04:01:40Z","timestamp":1689393700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals"],"prefix":"10.1186","volume":"22","author":[{"given":"Marco","family":"Tamborrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Pluschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"4638_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","volume":"24","author":"SJ Draper","year":"2018","unstructured":"Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018;24:43\u201356.","journal-title":"Cell Host Microbe"},{"key":"4638_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 2020;5:48.","journal-title":"NPJ Vaccines"},{"key":"4638_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14760584.2021.1882309","volume":"20","author":"DI Stanisic","year":"2021","unstructured":"Stanisic DI, McCall MBB. Correlates of malaria vaccine efficacy. Expert Rev Vaccines. 2021;20:143\u201361.","journal-title":"Expert Rev Vaccines"},{"key":"4638_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","journal-title":"Lancet"},{"key":"4638_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0140-6736(21)02235-2","volume":"398","author":"Editorial","year":"2021","unstructured":"Editorial. Malaria vaccine approval: a step change for global health. Lancet. 2021;398:1381.","journal-title":"Lancet"},{"key":"4638_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.pt.2020.04.003","volume":"36","author":"RJ Ragotte","year":"2020","unstructured":"Ragotte RJ, Higgins MK, Draper SJ. The RH5-CyRPA-Ripr complex as a malaria vaccine target. Trends Parasitol. 2020;36:545\u201359.","journal-title":"Trends Parasitol"},{"key":"4638_CR7","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.4049\/jimmunol.1103177","volume":"188","author":"AM Dreyer","year":"2012","unstructured":"Dreyer AM, Matile H, Papastogiannidis P, Kamber J, Favuzza P, Voss TS, et al. Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen. J Immunol. 2012;188:6225\u201337.","journal-title":"J Immunol"},{"key":"4638_CR8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1073\/pnas.1415466112","volume":"112","author":"KS Reddy","year":"2015","unstructured":"Reddy KS, Amlabu E, Pandey AK, Mitra P, Chauhan VS, Gaur D. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc Natl Acad Sci USA. 2015;112:1179\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4638_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chom.2016.06.004","volume":"20","author":"JC Volz","year":"2016","unstructured":"Volz JC, Yap A, Sisquella X, Thompson JK, Lim NT, Whitehead LW, et al. Essential role of the PfRh5\/PfRipr\/CyRPA complex during Plasmodium falciparum invasion of erythrocytes. Cell Host Microbe. 2016;20:60\u201371.","journal-title":"Cell Host Microbe"},{"key":"4638_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/s41564-022-01261-2","volume":"12","author":"SW Scally","year":"2022","unstructured":"Scally SW, Triglia T, Evelyn C, Seager BA, Pasternak M, Lim PS, et al. PCRCR complex is essential for invasion of human erythrocytes by Plasmodium falciparum. Nat Microbiol. 2022;12:2039\u201353.","journal-title":"Nat Microbiol"},{"key":"4638_CR11","doi-asserted-by":"publisher","first-page":"e0037721","DOI":"10.1128\/IAI.00377-21","volume":"90","author":"SY Mian","year":"2022","unstructured":"Mian SY, Somanathan A, Chaddha K, Pandey AK, Singh H, Krishna S, et al. Plasmodium falciparum cysteine-rich protective antigen (CyRPA) elicits detectable levels of invasion-inhibitory antibodies during natural infection in humans. Infect Immun. 2022;90:e0037721.","journal-title":"Infect Immun"},{"key":"4638_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198371","volume":"13","author":"FD Partey","year":"2018","unstructured":"Partey FD, Castberg FC, Sarbah EW, Silk SE, Awandare GA, Draper SJ, et al. Kinetics of antibody responses to PfRH5-complex antigens in ghanaian children with Plasmodium falciparum malaria. PLoS ONE. 2018;13:e0198371.","journal-title":"PLoS One"},{"key":"4638_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12936-016-1213-x","volume":"15","author":"P Favuzza","year":"2016","unstructured":"Favuzza P, Blaser S, Dreyer AM, Riccio G, Tamborrini M, Thoma R, et al. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA. Malar J. 2016;15:161.","journal-title":"Malar J"},{"key":"4638_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0158-9","volume":"5","author":"M Tamborrini","year":"2020","unstructured":"Tamborrini M, Hauser J, Sch\u00e4fer A, Amacker M, Favuzza P, Kyungtak K, et al. Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models. NPJ Vaccines. 2020;5: 9.","journal-title":"NPJ Vaccines"},{"key":"4638_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.879078","volume":"10","author":"B Fernandes","year":"2022","unstructured":"Fernandes B, Sousa M, Castro R, Sch\u00e4fer A, Hauser J, Schulze K, et al. Scalable process for high-yield production of PfCyRPA using insect cells for inclusion in a malaria virosome-based vaccine candidate. Front Bioeng Biotechnol. 2022;10: 879078.","journal-title":"Front Bioeng Biotechnol"},{"key":"4638_CR16","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.phytochem.2006.05.039","volume":"67","author":"S Ganapaty","year":"2006","unstructured":"Ganapaty S, Steve Thomas P, Karagianis G, Waterman PG, Brun R. Antiprotozoal and cytotoxic naphthalene derivatives from Diospyros assimilis. Phytochemistry. 2006;67:1950\u20136.","journal-title":"Phytochemistry"},{"key":"4638_CR17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.20383","volume":"6","author":"P Favuzza","year":"2017","unstructured":"Favuzza P, Guffart E, Tamborrini M, Scherer B, Dreyer AM, Rufer AC, et al. Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. Elife. 2017;6: e20383.","journal-title":"Elife"},{"key":"4638_CR18","unstructured":"Malaria Vaccine Funders Group. Malaria Vaccine technology roadmap. 2013."},{"key":"4638_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.chom.2008.06.001","volume":"1","author":"K Hayton","year":"2008","unstructured":"Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S, et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe. 2008;1:40\u201351.","journal-title":"Cell Host Microbe"},{"key":"4638_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijpara.2008.10.006","volume":"3","author":"J Baum","year":"2009","unstructured":"Baum J, Chen L, Healer J, Lopaticki S, Boyle M, Triglia T, et al. Reticulocyte-binding protein homologue 5\u2014an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol. 2009;3:371\u201380.","journal-title":"Int J Parasitol"},{"key":"4638_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002199","volume":"7","author":"L Chen","year":"2011","unstructured":"Chen L, Lopaticki S, Riglar DT, Dekiwadia C, Uboldi AD, Tham WH, et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog. 2011;7: e1002199.","journal-title":"PLoS Pathog"},{"key":"4638_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.vaccine.2012.10.106","volume":"31","author":"LY Bustamante","year":"2013","unstructured":"Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru M, Nguon C, et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine. 2013;31:373\u20139.","journal-title":"Vaccine"},{"key":"4638_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1128\/IAI.00970-13","volume":"1","author":"KS Reddy","year":"2014","unstructured":"Reddy KS, Pandey AK, Singh H, Sahar T, Emmanuel A, Chitnis CE, et al. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect Immun. 2014;1:152\u201364.","journal-title":"Infect Immun"},{"key":"4638_CR24","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1038\/s41598-020-67877-8","volume":"1","author":"Y Azasi","year":"2020","unstructured":"Azasi Y, Gallagher SK, Diouf A, Dabbs RA, Jin J, Mian SY, et al. Bliss\u2019 and Loewe\u2019s additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations. Sci Rep. 2020;1:11802.","journal-title":"Sci Rep"},{"key":"4638_CR25","doi-asserted-by":"publisher","first-page":"e96381","DOI":"10.1172\/jci.insight.96381","volume":"21","author":"RO Payne","year":"2017","unstructured":"Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017;21:e96381.","journal-title":"JCI Insight"},{"key":"4638_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41541-018-0071-7","volume":"3","author":"J Jin","year":"2018","unstructured":"Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ, et al. Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. NPJ Vaccines. 2018;3:32.","journal-title":"NPJ Vaccines"},{"key":"4638_CR27","first-page":"701","volume":"6","author":"AM Minassian","year":"2021","unstructured":"Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, et al. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med (NY). 2021;6:701\u201319.e19.","journal-title":"Med (NY)"},{"key":"4638_CR28","first-page":"e13030","volume":"7","author":"J Healer","year":"2019","unstructured":"Healer J, Wong W, Thompson JK, He W, Birkinshaw RW, Miura K, et al. Neutralising antibodies block the function of Rh5\/Ripr\/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes. Cell Microbiol. 2019;7:e13030.","journal-title":"Cell Microbiol"},{"key":"4638_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01254","volume":"10","author":"JJ Illingworth","year":"2019","unstructured":"Illingworth JJ, Alanine DG, Brown R, Marshall JM, Bartlett HE, Silk SE, et al. Functional comparison of blood-stage Plasmodium falciparum malaria vaccine candidate antigens. Front Immunol. 2019;10: 1254.","journal-title":"Front Immunol"},{"key":"4638_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41467-022-28601-4","volume":"1","author":"RJ Ragotte","year":"2022","unstructured":"Ragotte RJ, Pulido D, Lias AM, Quinkert D, Alanine DGW, Jamwal A, et al. Heterotypic interactions drive antibody synergy against a malaria vaccine candidate. Nat Commun. 2022;1:933.","journal-title":"Nat Commun"},{"key":"4638_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1049065","volume":"12","author":"J Healer","year":"2022","unstructured":"Healer J, Thompson JK, Mackwell KL, Browne CD, Seager BA, Ngo A, et al. RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting. Front Cell Infect Microbiol. 2022;12: 1049065.","journal-title":"Front Cell Infect Microbiol"},{"key":"4638_CR32","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.21347","volume":"6","author":"L Chen","year":"2017","unstructured":"Chen L, Xu Y, Wong W, Thompson JK, Healer J, Goddard-Borger ED, et al. Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA. Elife. 2017;6: e21347.","journal-title":"Elife"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04638-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04638-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04638-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T04:02:05Z","timestamp":1689393725000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04638-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4638"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04638-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mice experiments at the Swiss Tropical and Public Health Institute were carried out in accordance with the national regulations for the protection of animal rights. The protocols were ethically approved by the veterinary office of the county of Basel-City, Switzerland (Permit Number 2375). Animal facilities of Eurogentec are accredited by the Belgian authorities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}